Ppt chapter 35
-
Upload
stanbridge -
Category
Documents
-
view
112 -
download
1
description
Transcript of Ppt chapter 35
![Page 1: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/1.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Chapter 35
Drugs Affecting the Lower Respiratory System
Chapter 35
Drugs Affecting the Lower Respiratory System
![Page 2: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/2.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Physiology Physiology
• The lower respiratory tract is virtually sterile because of the various defense mechanisms in the upper respiratory system.
• Protective mechanisms
– All the tubes in the lower airway contain goblet cells, which secrete mucus to entrap any particles.
– Microorganisms and other foreign bodies are removed from the air by tiny hair-like structures called cilia.
• Gas exchange, perfusion, and respiration
– Lung tissue receives its blood supply from the bronchial artery, which branches directly off the thoracic aorta.
• Ventilation
– The act of breathing is controlled by the central nervous system (CNS).
![Page 3: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/3.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Lower Respiratory TractLower Respiratory Tract
![Page 4: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/4.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Pathophysiology Pathophysiology
• Acute bronchitis is caused most frequently by viruses.
• Asthma is a disorder characterized by recurrent episodes of bronchospasm, bronchial muscle spasm that leads to narrowed or obstructed airways.
• Chronic airway limitation (CAL) is an umbrella term that describes gradually progressive, degenerative diseases, such as chronic bronchitis, emphysema, or repeated, severe asthma attacks.
• Chronic bronchitis is long-standing, largely irreversible inflammation of the bronchial tree.
![Page 5: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/5.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Pathophysiology (cont.)Pathophysiology (cont.)
• Emphysema is an abnormal distention of the lungs with air characterized by loss or degeneration of elastic tissue, disappearance of capillary walls, and breakdown of the alveolar walls.
• Pneumonia is an inflammation of the lungs. It can be caused by bacterial or viral invasion of the tissue or by aspiration of foreign substances into the lower respiratory tract.
• Cystic fibrosis is a hereditary disease that affects the functioning of the body’s exocrine glands: the mucus-secreting and sweat glands.
![Page 6: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/6.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Mucolytic Drugs Mucolytic Drugs
• Mucolytics break down mucus.
• The drugs can be administered by a nebulizer or by direct instillation into the trachea.
• Mucolytics usually are reserved for patients who have major difficulty mobilizing and coughing up secretions.
• Prototype drug: acetylcysteine (Mucomyst)
![Page 7: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/7.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetylcysteine: Core Drug Knowledge Acetylcysteine: Core Drug Knowledge
• Pharmacotherapeutics
– Used to liquefy the thick, tenacious secretions.
• Pharmacokinetics
– Administered: inhalation. Onset: 1 minute.
• Pharmacodynamics
– It splits disulfide bonds that are responsible for holding the mucous material together.
![Page 8: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/8.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetylcysteine: Core Drug Knowledge (cont.)Acetylcysteine: Core Drug Knowledge (cont.)
• Contraindications and precautions
– Hypersensitive
• Adverse effects
– Bronchospasm, bronchoconstriction, chest tightness, a burning feeling in the upper airway, and rhinorrhea
• Drug interactions
– No important drug interactions have been reported for acetylcysteine .
![Page 9: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/9.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetylcysteine: Core Patient Variables Acetylcysteine: Core Patient Variables
• Health status
– Perform a physical examination to establish baselines.
• Life span and gender
– Determine pregnancy and lactation status.
• Environment
– Usually given in a supervised environment
![Page 10: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/10.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetylcysteine: Nursing Diagnoses and Outcomes Acetylcysteine: Nursing Diagnoses and Outcomes
• Ineffective Airway Clearance related to drug effect or bronchospasm
– Desired outcome: The patient’s airway will be maintained without increased difficulty breathing.
• Disturbed Sensory Perception, Olfactory, related to odor of drug and route of administration
– Desired outcome: The patient will remain comfortable and able to tolerate drug therapy.
![Page 11: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/11.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetylcysteine: Nursing Diagnoses and Outcomes (cont.)Acetylcysteine: Nursing Diagnoses and Outcomes (cont.)
• Imbalanced Nutrition: Less than Body Requirements, related to nausea and vomiting.
– Desired outcome: The patient will maintain nutritional balance throughout therapy.
• Risk for Injury related to anaphylactoid reaction
– Desired outcome: Potential anaphylactoid reactions will be recognized and treated appropriately.
![Page 12: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/12.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetylcysteine: Planning and InterventionsAcetylcysteine: Planning and Interventions
• Maximizing therapeutic effects
– Administer an inhaled beta-agonist before administering acetylcysteine.
• Minimizing adverse effects
– Inform the patient that nebulization may produce an initially disagreeable odor, but that this odor is transient.
![Page 13: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/13.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetylcysteine: Teaching, Assessment, and EvaluationAcetylcysteine: Teaching, Assessment, and Evaluation• Patient and family education
– Explain the rationale for receiving acetylcysteine.
– Inform patients that they must not take this drug without the assistance of a respiratory therapist.
– Teach patients and their family members all aspects of pulmonary hygiene.
• Ongoing assessment and evaluation
– For the patient receiving acetylcysteine for its mucolytic effects, assess the patient for proper techniques of pulmonary hygiene and respiratory status.
![Page 14: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/14.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
• Acetylcysteine is administered by
– A. Inhalation
– B. SC
– C. Oral
– D. IV
![Page 15: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/15.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
• A. Inhalation
• Rationale: Acetylcysteine is delivered directly to the respiratory system by nebulizer (inhalation) or direct instillation.
![Page 16: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/16.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Bronchodilators Bronchodilators
• Bronchodilators are drugs used to facilitate respiration by dilating the airways.
• Bronchodilators may be administered orally, parenterally, or by inhalation.
• Inhalation is the most frequent method using metered-dose inhalers (MDIs) or dry-powder inhalers (DPIs).
• Beta-agonists (sympathomimetics)
– One of the actions of beta stimulation in the sympathetic nervous system is dilation of the bronchi and increased rate and depth of respiration.
• Prototype drug: albuterol (Proventil, Ventolin)
![Page 17: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/17.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Albuterol: Core Drug Knowledge Albuterol: Core Drug Knowledge
• Pharmacotherapeutics
– Bronchodilator in managing CAL and asthma
• Pharmacokinetics
– Administered: inhalation. Excreted: urine and feces. Onset: 5 to 15 minutes.
• Pharmacodynamics
– It selectively stimulates receptors of the smooth muscle in the lungs, the uterus, and the vasculature that supplies the skeletal muscle.
![Page 18: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/18.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Albuterol: Core Drug Knowledge (cont.)Albuterol: Core Drug Knowledge (cont.)
• Contraindications and precautions
– Hypersensitivity
• Adverse effects
– Tachycardia, palpitations, anxiety, tremors, headache, insomnia, muscle cramps, and gastrointestinal (GI) symptoms
• Drug interactions
– Other sympathomimetic agents, beta-adrenergic blocking agents, digoxin, antidepressants, and potassium-losing diuretics
![Page 19: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/19.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Albuterol: Core Patient Variables Albuterol: Core Patient Variables
• Health status
– Assess medical condition and contraindications to therapy.
• Life span and gender
– Pregnancy Category C drug
• Lifestyle, diet, and habits
– Assess caffeine intake.
• Environment
– Frequently given at home
![Page 20: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/20.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Albuterol: Nursing Diagnoses and Outcomes Albuterol: Nursing Diagnoses and Outcomes
• Anxiety related to sympathomimetic effects of albuterol administration
– Desired outcome: The patient will engage in interventions that decrease anxiety.
• Ineffective Tissue Perfusion: Cardiopulmonary related to rebound bronchoconstriction caused by overuse of albuterol
– Desired outcome: The patient will use albuterol as prescribed by the health care provider and contact that person if symptoms do not abate.
![Page 21: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/21.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Albuterol: Planning and InterventionsAlbuterol: Planning and Interventions
• Maximizing therapeutic effects
– To obtain the correct dose of albuterol, prime the device.
• Minimizing adverse effects
– The patient should be encouraged to contact the health care provider to obtain adjunctive medications if symptoms persist, rather than increase the frequency of albuterol use.
![Page 22: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/22.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Albuterol: Teaching, Assessment, and EvaluationAlbuterol: Teaching, Assessment, and Evaluation
• Patient and family education
– Teach patients that inhaled albuterol is called a “rescue drug.”
– Teach patients how to use an MDI.
– Explain the importance of limiting caffeine intake.
• Ongoing assessment and evaluation
– Evaluate for the symptoms of asthma or CAL in patients using albuterol.
![Page 23: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/23.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
• Albuterol is given for acute exacerbation of CAL or asthma.
– A. True
– B. False
![Page 24: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/24.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
• A. True
• Rationale: Albuterol is considered a “rescue inhaler” and is used for acute exacerbations of lung disease.
![Page 25: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/25.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Respiratory Anticholinergic Agents Respiratory Anticholinergic Agents
• Inhaled anticholinergic drugs are considered first-line treatment for patients with CAL.
• Anticholinergic agents diminish the effect of acetylcholine.
• In the respiratory system, use of inhaled anticholinergic drugs stops the bronchoconstriction.
• Prototype drug: ipratropium bromide (Atrovent)
![Page 26: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/26.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ipratropium Bromide: Core Drug Knowledge Ipratropium Bromide: Core Drug Knowledge
• Pharmacotherapeutics
– Used for maintenance treatment of bronchospasm
• Pharmacokinetics
– Administered: inhalation. Onset: 15 to 30 minutes.
• Pharmacodynamics
– Antagonizes the action of acetylcholine by blocking muscarinic cholinergic receptors
![Page 27: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/27.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ipratropium Bromide: Core Drug Knowledge (cont.)Ipratropium Bromide: Core Drug Knowledge (cont.)
• Contraindications and precautions
– Sensitivity to ipratropium and atropine
• Adverse effects
– Paradoxic acute bronchospasm, cough, hoarseness, throat irritation, or dysgeusia
• Drug interactions
– No serious drug–drug interactions are associated with ipratropium
![Page 28: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/28.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ipratropium Bromide: Core Patient Variables Ipratropium Bromide: Core Patient Variables
• Health status
– Assess for medical complication to therapy.
• Life span and gender
– Pregnancy Category B drug
• Lifestyle, diet, and habits
– Determine if the patient smokes.
• Environment
– Administered at home
![Page 29: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/29.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ipratropium Bromide: Nursing Diagnoses and Outcomes Ipratropium Bromide: Nursing Diagnoses and Outcomes
• Risk for Injury (bronchospasm) related to use of new canister of ipratropium
– Desired outcome: The patient will “test-spray” a new canister three times before inhaling the medication.
• Risk for Injury (anaphylactoid reactions) related to allergies to soybeans, legumes, or soya lecithin.
– Desired outcome: The patient will review past allergic responses to assess whether any of the causative foods may have been responsible.
![Page 30: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/30.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ipratropium Bromide: Planning and InterventionsIpratropium Bromide: Planning and Interventions
• Maximizing therapeutic effects
– Explain the importance of taking ipratropium daily, despite the absence of symptoms.
• Minimizing adverse effects
– Explain the importance of using the MDI as prescribed to avoid systemic absorption that leads to an increased risk of adverse effects.
![Page 31: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/31.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ipratropium Bromide: Teaching, Assessment, and EvaluationIpratropium Bromide: Teaching, Assessment, and Evaluation
• Patient and family education
– Advise patients that ipratropium is used prophylactically.
– Remind patients that overuse of ipratropium may induce adverse effects.
• Ongoing assessment and evaluation
– Assess the patient’s need for beta-agonist drugs in addition to ipratropium.
![Page 32: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/32.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
• Patients with hypersensitivity to ________ cannot use ipratropium bromide.
– A. Dairy
– B. Eggs
– C. Wheat
– D. Legumes
![Page 33: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/33.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
– D. Legumes
– Rationale: A major contraindication for taking ipratropium bromide is a hypersensitivity to legumes, such as soybeans or peanuts.
![Page 34: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/34.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Xanthine Derivatives Xanthine Derivatives
• The xanthine derivatives, including theophylline, aminophylline, diphylline, and caffeine, come from a variety of naturally occurring sources.
• They are excellent bronchodilators but do not work as rapidly as beta-adrenergic agonist drugs.
• Prototype drug: theophylline (Elixophyllin, Theo24, Uniphyl)
![Page 35: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/35.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Theophylline: Core Drug Knowledge Theophylline: Core Drug Knowledge
• Pharmacotherapeutics
– Indicated for the symptomatic relief or prevention of bronchial asthma and reversal of bronchospasm
• Pharmacokinetics
– Administered: oral or IV. Metabolism: liver. Excreted: kidneys. Peak: 2 hours.
• Pharmacodynamics
– It is believed that bronchodilation is caused by inhibition of phosphodiesterase.
![Page 36: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/36.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Theophylline: Core Drug Knowledge (cont.)Theophylline: Core Drug Knowledge (cont.)
• Contraindications and precautions
– Hypersensitivity, status asthmaticus, or peptic ulcer
• Adverse effects
– Adverse effects related to theophylline use are related directly to serum levels of the drug.
• Drug interactions
– Multiple drug interactions
![Page 37: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/37.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Theophylline: Core Patient Variables Theophylline: Core Patient Variables
• Health status
– Assess for contraindications to therapy.
• Life span and gender
– Assess pregnancy and lactation status.
• Lifestyle, diet, and habits
– Assess if the patient smokes.
• Environment
– IV formulation given in acute care setting
![Page 38: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/38.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Theophylline: Nursing Diagnoses and Outcomes Theophylline: Nursing Diagnoses and Outcomes • Disturbed Sensory Perception: Kinesthetic related to CNS
effects of irritability, insomnia, and dizziness
– Desired outcome: The patient will be protected from injury caused by CNS effects, such as dizziness and loss of balance.
• Ineffective Tissue Perfusion: Cardiopulmonary related to cardiac effects of the drug
– Desired outcome: Adverse effects will be limited by proper administration and monitoring of drug serum levels.
• Risk for Injury related to headache, GI effects, and CNS effects
– Desired outcome: The patient will develop strategies to be able to tolerate the drug and remain injury-free during drug therapy.
![Page 39: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/39.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Theophylline: Planning and InterventionsTheophylline: Planning and Interventions
• Maximizing therapeutic effects
– In the hospital setting, administer theophylline at a rate of 20 mg/minute.
• Minimizing adverse effects
– Monitor serum theophylline levels carefully and discuss dosage adjustment.
– Administer immediate-release preparations with a meal to decrease GI distress.
![Page 40: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/40.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Theophylline: Teaching, Assessment, and EvaluationTheophylline: Teaching, Assessment, and Evaluation
• Patient and family education
– Explain that theophylline will help make breathing easier.
– Explain the importance of taking theophylline exactly as prescribed.
• Ongoing assessment and evaluation
– Monitor the patient taking theophylline for potential adverse CNS and cardiovascular effects.
![Page 41: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/41.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
• Theophylline serum levels should be _______ to prevent adverse reactions.
– A. Less than 10 mcg/mL
– B. Less than 20 mcg/mL
– C. Less than 40 mcg/mL
– D. Less than 60 mcg/mL
![Page 42: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/42.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
• B. Less than 20 mcg/mL
• Rationale: Adverse effects related to theophylline use are related directly to serum levels of the drug. At serum levels less than 20 mcg/mL, adverse effects are uncommon.
![Page 43: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/43.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anti-Inflammatory Agents Anti-Inflammatory Agents
• In addition to bronchodilators, anti-inflammatory agents are used to manage respiratory disorders, especially asthma.
• Inhaled glucocorticoid steroids
– Glucocorticoid steroids are the most effective anti-inflammatory drugs available for managing respiratory disorders.
– They can be given orally, parenterally, or by inhalation.
– Inhaled corticosteroid (ICS) agents have become first-line treatment for persistent asthma.
• Prototype drug: flunisolide (AeroBid)
![Page 44: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/44.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Flunisolide: Core Drug Knowledge Flunisolide: Core Drug Knowledge
• Pharmacotherapeutics
– Used to prevent bronchospasm
• Pharmacokinetics
– Administered: parenteral, oral, or by inhalation.
• Pharmacodynamics
– Inhibit the production of leukotrienes and prostaglandins through interference with arachidonic acid metabolism.
![Page 45: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/45.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Flunisolide: Core Drug Knowledge (cont.)Flunisolide: Core Drug Knowledge (cont.)
• Contraindications and precautions
– Active systemic fungal infection
• Adverse effects
– Sore throat, hoarseness, coughing, dry mouth, and pharyngeal and laryngeal fungal infections
• Drug interactions
– No important drug–drug interactions occur with flunisolide.
![Page 46: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/46.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Flunisolide: Core Patient Variables Flunisolide: Core Patient Variables
• Health status
– Assess signs of active lung infection.
• Life span and gender
– Pregnancy Category C drug
• Lifestyle, diet, and habits
– Caution about smoking.
• Environment
– Given in home care setting
![Page 47: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/47.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Flunisolide: Nursing Diagnoses and Outcomes Flunisolide: Nursing Diagnoses and Outcomes
• Impaired Verbal Communication related to dysphonia and cough
– Desired outcome: The patient will report symptoms to the health care provider.
• Risk for Infection related to immunosuppression
– Desired outcome: The patient will remain free of infection throughout therapy.
![Page 48: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/48.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Flunisolide: Planning and InterventionsFlunisolide: Planning and Interventions
• Maximizing therapeutic effects
– Instruct the patient to take flunisolide every day, regardless of how well the patient feels.
– Using a beta-2 agonist before flunisolide dilates the bronchial tree
• Minimizing adverse effects
– Spacers may help alleviate dysphonia by filtering larger aerosol particles.
![Page 49: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/49.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Flunisolide: Teaching, Assessment, and EvaluationFlunisolide: Teaching, Assessment, and Evaluation
• Patient and family education
– Patient education is important for inhaled steroid therapy.
– Importance of daily use, regardless of the absence of symptoms
• Ongoing assessment and evaluation
– Assess for a decreased incidence of acute asthma attacks.
![Page 50: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/50.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
• Patients using flunisolide are at a high risk for developing
– A. Oral bacterial infection
– B. Oral viral infection
– C. Oral fungal infection
![Page 51: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/51.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
• C. Oral fungal infection
• Rationale: Oropharyngeal Candida albicans infection is a common adverse effect associated with daily use of ICS.
![Page 52: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/52.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Mast Cell Stabilizers Mast Cell Stabilizers
• Vasoactive substances, such as histamine, serotonin, bradykinin, and leukotrienes, are located within the mast cell.
• When the mast cell ruptures, these substances cause an inflammatory response, such as bronchial constriction, which accounts for the symptoms of an acute asthma attack.
• Prototype drug: cromolyn sodium
![Page 53: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/53.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Cromolyn Sodium: Core Drug Knowledge Cromolyn Sodium: Core Drug Knowledge
• Pharmacotherapeutics
– Prophylactic agent in treating mild-to-moderate asthma
• Pharmacokinetics
– Administered: inhalation or oral. Distribution: lungs. Excreted: feces.
• Pharmacodynamics
– Works at the surface of the mast cell to inhibit mast cell rupture and degranulation after contact with an antigen
![Page 54: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/54.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Cromolyn Sodium: Core Drug Knowledge (cont.)Cromolyn Sodium: Core Drug Knowledge (cont.)
• Contraindications and precautions
– Hypersensitivity
• Adverse effects
– Bronchospasm, throat irritation, and cough
• Drug interactions
– No clinically important drug interactions are known with cromolyn sodium.
![Page 55: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/55.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Cromolyn Sodium: Core Patient Variables Cromolyn Sodium: Core Patient Variables
• Health status
– Evaluate for previous reaction to the drug.
• Life span and gender
– Pregnancy Category B drug
• Lifestyle, diet, and habits
– Monitor for lactose intolerance.
• Environment
– Assess the environment where the drug will be given.
![Page 56: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/56.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Cromolyn Sodium: Nursing Diagnoses and Outcomes Cromolyn Sodium: Nursing Diagnoses and Outcomes
• Imbalanced Nutrition: Less than Body Requirements related to nausea and vomiting, bloating, abdominal cramps, and flatulence
– Desired outcome: The patient will maintain body weight throughout therapy.
• Ineffective Breathing Pattern related to bronchospasm and cough
– Desired outcome: The patient will have a patent airway throughout therapy.
![Page 57: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/57.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Cromolyn Sodium: Planning and InterventionsCromolyn Sodium: Planning and Interventions
• Maximizing therapeutic effects
– Cromolyn sodium is used for long-term management of respiratory disorders.
• Minimizing adverse effects
– Caution patients who have a known intolerance to lactose.
![Page 58: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/58.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Cromolyn Sodium: Teaching, Assessment, and EvaluationCromolyn Sodium: Teaching, Assessment, and Evaluation
• Patient and family education
– Emphasize that cromolyn sodium is not useful for managing acute symptoms.
– Teach the patient how to use a peak flow meter to monitor his or her personal respiratory status.
• Ongoing assessment and evaluation
– Evaluate the effectiveness of cromolyn sodium, demonstrated by a decrease in the frequency and severity of symptoms.
![Page 59: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/59.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
• The patient has been prescribed cromolyn sodium for exercise-induced asthma. What would you teach about administration of this medication?
– A. Take medication daily
– B. Only take medication if you are having symptoms
– C. Take during exercise to prevent symptoms
– D. Take 15 to 20 minutes before exercise
![Page 60: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/60.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
• D. Take 15 to 20 minutes before exercise
• Rationale: Advise patients who experience exercise-induced bronchospasm to take cromolyn sodium 15 to 20 minutes before exercise.
![Page 61: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/61.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Leukotriene Receptor Antagonists Leukotriene Receptor Antagonists
• Leukotrienes are inflammatory mediators that are powerful bronchoconstrictors and vasodilators.
• Leukotrienes have been identified as important mediators in the pathology and symptomatology of asthma
• Result in airway hyperreactivity, bronchoconstriction, and hypersecretion
• Prototype drug: zafirlukast (Accolate)
![Page 62: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/62.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Zafirlukast: Core Drug Knowledge Zafirlukast: Core Drug Knowledge
• Pharmacotherapeutics
– Prophylaxis or treatment of chronic asthma
• Pharmacokinetics
– Administered: oral. Metabolism: liver. Excreted: urine and feces.
• Pharmacodynamics
– Blocks receptors for the leukotrienes bound to the amino acid cysteine
![Page 63: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/63.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Zafirlukast: Core Drug Knowledge (cont.)Zafirlukast: Core Drug Knowledge (cont.)
• Contraindications and precautions
– Hypersensitivity
• Adverse effects
– Headache, gastritis, pharyngitis, and rhinitis
• Drug interactions
– Theophylline, warfarin, aspirin, erythromycin, and drugs metabolized through the P-450 CYP2C9
![Page 64: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/64.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Zafirlukast: Core Patient Variables Zafirlukast: Core Patient Variables
• Health status
– Assess medical status and liver function.
• Life span and gender
– Pregnancy Category B drug
• Lifestyle, diet, and habits
– Take medication on an empty stomach.
• Environment
– Generally given at home
![Page 65: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/65.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Zafirlukast: Nursing Diagnoses and Outcomes Zafirlukast: Nursing Diagnoses and Outcomes • Risk for Injury (poisoning) related to interaction between
drugs metabolized by the P-450 enzyme system
– Desired outcome: The patient will adhere to dosage adjustment of medications, undergo serial laboratory testing, and report adverse effects immediately to the health care provider.
• Diarrhea related to drug therapy
– Desired outcome: The patient will remain well hydrated throughout therapy.
• Acute Pain related to drug therapy
– Desired outcome: The patient will take nonnarcotic analgesics if headache occurs.
![Page 66: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/66.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Zafirlukast: Planning and InterventionsZafirlukast: Planning and Interventions
• Maximizing therapeutic effects
– Ensure that the patient takes zafirlukast twice daily despite the absence of symptoms.
• Minimizing adverse effects
– Ensure that the patient takes the medication only as prescribed.
![Page 67: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/67.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Zafirlukast: Teaching, Assessment, and EvaluationZafirlukast: Teaching, Assessment, and Evaluation
• Patient and family education
– Explain that zafirlukast is used in maintenance therapy.
– Encourage patients to take nonnarcotic analgesics if headache occurs.
• Ongoing assessment and evaluation
– Assess whether the patient needs beta-agonist drugs in addition to zafirlukast.
![Page 68: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/68.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
• Zafirlukast is used for
– A. Prophylaxis
– B. Acute attack
– C. Infection
– D. All of the above
![Page 69: Ppt chapter 35](https://reader033.fdocuments.us/reader033/viewer/2022061205/54816cbcb479594b578b486a/html5/thumbnails/69.jpg)
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
• A. Prophylaxis
• Rationale: Zafirlukast is used as prophylaxis or for treating chronic asthma.